{"id":"ak101","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL4650437","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AK101 functions as a T-cell engager by binding CD3 on cytotoxic T lymphocytes while simultaneously targeting prostate-specific membrane antigen (PSMA) on cancer cells. This dual binding brings T cells into close proximity with tumor cells, triggering T-cell activation and cytotoxic killing of PSMA-positive malignancies. The bispecific design enables potent anti-tumor immunity without requiring prior T-cell engineering.","oneSentence":"AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect immune attack against PSMA-expressing cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:22.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/AK-101","title":"AK-101","extract":"The AK-101 is a Kalashnikov assault rifle model developed in 1994 to use the 5.56×45mm NATO cartridge belonging to the export AK-100."},"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"}]},"trialDetails":[{"nctId":"NCT04172233","phase":"PHASE1, PHASE2","title":"A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Akeso","startDate":"2018-01-09","conditions":"Plaque Psoriasis","enrollment":96},{"nctId":"NCT04173637","phase":"PHASE2","title":"Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-12-19","conditions":"Plaque Psoriasis","enrollment":330},{"nctId":"NCT05509361","phase":"PHASE3","title":"Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-04-08","conditions":"Plaque Psoriasis","enrollment":950},{"nctId":"NCT06281704","phase":"PHASE1","title":"A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Akeso","startDate":"2020-11-26","conditions":"Ulcerative Colitis","enrollment":34},{"nctId":"NCT05120297","phase":"PHASE3","title":"A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-11-29","conditions":"Psoriasis Vulgaris","enrollment":452}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AK101","genericName":"AK101","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect immune attack against PSMA-expressing cancers. Used for Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}